Proceedings from the 9th Annual Winter Lung Cancer Conference
Proceedings from the 9th Annual Winter Lung Cancer Conference
Proceedings from the 9th Annual Winter Lung Cancer Conference
Proceedings from the 9th Annual Winter Lung Cancer Conference
Proceedings from the 9th Annual Winter Lung Cancer Conference
Proceedings from the 9th Annual Winter Lung Cancer Conference
Proceedings from the 9th Annual Winter Lung Cancer Conference
Proceedings from the 9th Annual Winter Lung Cancer Conference
Proceedings from the 9th Annual Winter Lung Cancer Conference
Proceedings from the 9th Annual Winter Lung Cancer Conference
Proceedings from the 9th Annual Winter Lung Cancer Conference
Excerpts from Rounds with the Investigators Multiple Myeloma and Lung Cancer Meetings, 2012
Excerpts from 2012 Rounds with the Investigators Multiple Myeloma, Lung Cancer and Breast Cancer Meetings
Rounds with Investigators 2012 | Multiple Myeloma — Link #7
Rounds with the Investigators 2012 | Multiple Myeloma
Rounds with Investigators 2012 | Multiple Myeloma — Link #6
Rounds with the Investigators 2012 | Multiple Myeloma
QUESTION: What is the best risk stratification test: cytogenetics, FISH, MyPRS™ GEP70, other GEP tests or “other”?
DR RAFAEL FONSECA: The question is a very pertinent one because I think more and more people have moved away from conventional or classic cytogenetics and I think there’s a good reason for that. Sure enough, if they’re abnormal, you know that the patient has very high-risk disease. But the yield for abnormalities, this is about 8 to 9% of cases that you get informative metaphases. So it’s, for the most part, it’s just wasting money, the other 90% of patients.
Rounds with Investigators 2012 | Multiple Myeloma — Link #5
Rounds with the Investigators 2012 | Multiple Myeloma
QUESTION: Has anybody collated a series of unusual fractures in patients on long-term bisphosphonates?
DR NEIL LOVE: So, Steve, can you comment on the other question you were asking about fractures?